Advertisement

Gastric Cancer

, Volume 21, Issue 6, pp 1024–1030 | Cite as

Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center

  • Yosuke Kano
  • Manabu Ohashi
  • Naoki Hiki
  • Daisuke Takahari
  • Keisho Chin
  • Kensei Yamaguchi
  • Yasuo Tsuda
  • Yoshiaki Shoji
  • Itaru Yasufuku
  • Kojiro Eto
  • Satoshi Ida
  • Koshi Kumagai
  • Souya Nunobe
  • Takeshi Sano
Original Article
  • 575 Downloads

Abstract

Background

One-year adjuvant S-1 monotherapy following D2 gastrectomy has been the Japanese treatment standard for pathological stage II or III gastric cancer since the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) was concluded in 2007. Trial patients were selected according to the 13th edition of the Japanese classification (JC-13). The JC-13 and the TNM classification underwent major revisions in 2010 (JC-14/TNM-7). However, neither the recent therapeutic results for patients with stage II/III disease defined by the current system nor comparisons with the ACTS-GC-results have been reported.

Methods

The 390 study patients had pathological stage II/III gastric cancer defined by the JC-14/TNM-7 and treated with S-1 following D2 gastrectomy between 2008 and 2012. The completion rate of 1-year S-1, first relapse site, and stage-specific survival according to the JC-14/TNM-7, JC-13, and TNM-6 were examined and the results compared with those of the ACTS-GC.

Results

The completion rate for 1-year S-1 (69.5%) was slightly higher than in the ACTS-GC. The recurrence pattern was almost identical. The 5-year overall survival rates of pathological IIA, IIB, IIIA, IIIB, and IIIC in the JC-14/TNM-7 were 96.0, 85.5, 81.8, 72.0, and 51.1%, respectively. Their 5-year overall and relapse-free survival rates by the JC-13 and TNM-6 systems were favorable as compared to those of ACTS-GC patients for all substages.

Conclusions

Survival outcome shown in this study of patients treated with 1-year adjuvant S-1 after D2 gastrectomy at a high-volume cancer hospital will provide a reference for future adjuvant trials targeting JC-14/TNM-7 stage II/III disease.

Keywords

Gastric cancer S-1 Adjuvant chemotherapy ACTS-GC 

Notes

Funding

The authors declare that this study had no external funding.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical standards

All procedures followed were in accordance with the ethical standards of the institutional and national committees governing human experimentation and in compliance with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consent or an appropriate substitute was obtained from all patients prior to their inclusion in the study.

References

  1. 1.
    International Research Agency on Cancer. The GLOBOCAN Project. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 1 Dec 2017.
  2. 2.
    National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Gastric cancer version 3. 2016.Google Scholar
  3. 3.
    Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4). Japanese Gastric Cancer Association Gastric Cancer. 2017;20:1–19.Google Scholar
  4. 4.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefGoogle Scholar
  5. 5.
    Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefGoogle Scholar
  6. 6.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1998;1:10–24.CrossRefGoogle Scholar
  7. 7.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 13th ed. Tokyo: Kanehara; 1998 (in Japanese).Google Scholar
  8. 8.
    Beahrs OH, Henson DH, Hutter RVP, Kennedy BJ. AJCC cancer staging manual. 4th ed. Philadelphia: Lippincott Company; 1992.Google Scholar
  9. 9.
    Hermanek P, Sobin LH. TNM classification of malignant tumors (UICC), 4th ed. Berlin: Springer; 1987.Google Scholar
  10. 10.
    Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven; 1997.Google Scholar
  11. 11.
    Sobin LH, Wittekind CH. TNM classification of malignant tumors (UICC), 5th ed. New York: Wiley; 1997.Google Scholar
  12. 12.
    Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101–12.CrossRefGoogle Scholar
  13. 13.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 14th ed. Tokyo: Kanehara; 2010 (in Japanese).Google Scholar
  14. 14.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual, 7th ed. Chicago: Springer; 2010.Google Scholar
  15. 15.
    Sobin LH, Wittekind C, Gospodarowicz M. TNM classification of malignant tumors (UICC), 7th ed. New York: Wiley; 2009.Google Scholar
  16. 16.
    Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual, 6th ed. New York: Springer; 2002.CrossRefGoogle Scholar
  17. 17.
    Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumors (UICC), 6th ed. New York: Wiley; 2002.Google Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  • Yosuke Kano
    • 1
  • Manabu Ohashi
    • 1
  • Naoki Hiki
    • 1
  • Daisuke Takahari
    • 2
  • Keisho Chin
    • 2
  • Kensei Yamaguchi
    • 2
  • Yasuo Tsuda
    • 1
  • Yoshiaki Shoji
    • 1
  • Itaru Yasufuku
    • 1
  • Kojiro Eto
    • 1
  • Satoshi Ida
    • 1
  • Koshi Kumagai
    • 1
  • Souya Nunobe
    • 1
  • Takeshi Sano
    • 1
  1. 1.Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
  2. 2.Department of Gastroenterological Medicine, Gastroenterological Center, Cancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations